Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Interim Safety Data Compared in Ixabepilone TITAN Trial

July 18th 2011

Researchers are continuing to explore whether ixabepilone (Ixempra) is a better choice as adjuvant chemotherapy for patients with early-stage, triple-negative breast cancer than the standard paclitaxel (Taxol).

Dr. Whelan Provides a MA.20 Trial Result Summary

July 14th 2011

Dr. Tim J. Whelan from Juravinski Cancer Centre Provides a MA.20 Trial Result Summary

Aiming for Immunity: New Therapies in Sights

July 14th 2011

Even before the FDA approved ipilimumab in March, the field of cancer immunotherapy was a lively area of scientific inquiry.

Dr. Hoos Describes Ipilimumab and Future Immunotherapies

July 13th 2011

Dr. Axel Hoos medical lead from Bristol-Myers Squibb Describes Ipilimumab and Future Immunotherapies

Tim Turnham on the Melanoma Research Foundation

July 12th 2011

Dr. Tim Turnham the executive director of the melanoma research foundation Describes the organization

Dr. Hoos on Tools Available to Measure Ipilimumab's Success

July 7th 2011

Dr. Axel Hoos from Bristol Myers-Squibb on Tools Available to Measure Ipilimumab's Success

Dr. Schuchter on the Next Steps in Melanoma Research

July 7th 2011

Dr. Lynn M. Schuchter from Penn Med on the Next Steps in Melanoma Research

Dr. Kris Talks About Defining Biomarkers

July 5th 2011

Dr. Mark G. Kris from memorial sloan-kettering Talks About the importance of Defining the broad term Biomarkers

Dr. Hoos Discusses the Clinical Kinetics of Immunotherapy

July 1st 2011

Dr. Axel Hoos the medical lead in Immunology/Oncology at Bristol-Myers Squibb Discusses the Clinical Kinetics of Immunotherapy

Routine Tests and Procedures in Cardiac Patients May Increase Cancer Risk

June 30th 2011

Researchers have reported that acute myocardial infarction (MI) patients who are exposed to low-dose ionizing radiation from imaging and therapeutic procedures may be at increased risk of cancer.

Donna Berry, PhD, RN 2011 ONS Distinguished Researcher Award Winner

June 29th 2011

Nurse scientist Donna Berry, PhD, RN, received the 2011 ONS Distinguished Researcher Award, which recognizes a nurse researcher whose work has enhanced the science and practice of oncology nursing.

Population Stratification and Cancer Risk Assessment: An Interview With Jill Barnholtz-Sloan, PhD

June 28th 2011

Population stratification refers to differences in allele frequencies between cases and controls, resulting from systematic differences in ancestry, as opposed to associations between genes and disease.

4 Questions for Martine Piccart-Gebhart, MD, PhD: Noted Breast Cancer Researcher Has Bright Hopes for HER2 Targets

June 27th 2011

Martine Piccart-Gebhart, MD, PhD is a professor of oncology at the Universite Libre de Bruxelles and director of the Medicine department at the Jules Bordet Institute in Brussels, Belgium.

Dr. Rini on the Results From His Axitinib and Sorafenib Trial

June 24th 2011

Dr. Brian Rini from the Cleveland Clinic Taussig Cancer Institute on the Results From His Axitinib and Sorafenib Trial

HER2 Signaling Beckons: Dimerization Process, Combination Therapies Highlight New Research

June 24th 2011

The first drug that successfully targeted the HER2 pathway in cancer treatment generated much excitement.

Dr. Infante on the Next Step in Melanoma Research

June 23rd 2011

Dr. Jeffrey Infante from Sarah Cannon Research Institute on the Next Step in Melanoma Research

Dr. Kris Discusses the Pemetrexed Trial Results

June 23rd 2011

Dr. Mark Kris from Memorial Sloan-Kettering Cancer Center Discusses the Pemetrexed Clincal Trial Results

Vismodegib Trial Yields Benefits in BCC patients

June 20th 2011

Vismodegib has demonstrated positive overall response rates in patients with advanced basal cell carcinoma.

Hedgehog Pathway Inhibitor GDC-0449 Reduces Lesion Size in Patients With Basal Cell Carcinoma

June 20th 2011

Patients with basal cell carcinoma had an eightfold decrease in lesion area when treated with GDC-0449

Smart Moves? E-patient Systems Rise Amid Skepticism

June 16th 2011

During the past 20 years, disease management systems have mushroomed in medicine